InvestorsHub Logo
Followers 12
Posts 1019
Boards Moderated 0
Alias Born 03/24/2013

Re: None

Sunday, 05/05/2013 3:19:07 AM

Sunday, May 05, 2013 3:19:07 AM

Post# of 427217
Liptruzet (atorva+ezetimibe) approval negative for AMRN
http://www.liptruzet.com/

in my opinion
patients with high TG and High LDL have got yet another alternative.
Though only LOVAZA is the direct competitor of Vascepa, cheaper statin combos do and will certainly limit the likes of Vascepa and Lovaza turning into multi-billion dollar drugs.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News